Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Removal of anti-Galα1,3Gal xenoantibodies with an injectable polymer
Andreas G. Katopodis, Richard G. Warner, Rudolf O. Duthaler, Markus B. Streiff, Armin Bruelisauer, Olivier Kretz, Birgit Dorobek, Elke Persohn, Hendrik Andres, Alain Schweitzer, Gebhard Thoma, Willy Kinzy, Valerie F.J. Quesniaux, Emanuele Cozzi, Hugh F.S. Davies, Rafael Mañez, David White
Andreas G. Katopodis, Richard G. Warner, Rudolf O. Duthaler, Markus B. Streiff, Armin Bruelisauer, Olivier Kretz, Birgit Dorobek, Elke Persohn, Hendrik Andres, Alain Schweitzer, Gebhard Thoma, Willy Kinzy, Valerie F.J. Quesniaux, Emanuele Cozzi, Hugh F.S. Davies, Rafael Mañez, David White
View: Text | PDF
Article

Removal of anti-Galα1,3Gal xenoantibodies with an injectable polymer

  • Text
  • PDF
Abstract

Research Article

Authors

Andreas G. Katopodis, Richard G. Warner, Rudolf O. Duthaler, Markus B. Streiff, Armin Bruelisauer, Olivier Kretz, Birgit Dorobek, Elke Persohn, Hendrik Andres, Alain Schweitzer, Gebhard Thoma, Willy Kinzy, Valerie F.J. Quesniaux, Emanuele Cozzi, Hugh F.S. Davies, Rafael Mañez, David White

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Baboons (n = 3) received intravenous injections of GAS914 at the times i...
Baboons (n = 3) received intravenous injections of GAS914 at the times indicated by arrows. Heavy arrows indicate injection of 5 mg/kg and light arrows indicate injection of 1 mg/kg. Anti-αGal IgM (circles), IgG (triangles), and HAPAb (squares) titers relative to human standard are shown (see Methods). Data from a single baboon are shown; the other two animals had a similar response.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts